- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.05. | Cancer drugmaker iTeos to shut down | ||
| 28.05. | Muscle-sparing obesity drug safe for Phase 3 trial, Veru says | ||
| 28.05. | FDA leaders seek industry input on 'listening tour' | ||
| 28.05. | GSK-licensed antibiotic meets goal in late-stage study | ||
| 28.05. | GLP-1 prescriptions for weight loss soar, despite obstacles | ||
| 28.05. | [Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care | ||
| 27.05. | FDA sets COVID vaccine formula as RFK Jr. narrows guidance for shots | ||
| 27.05. | Lilly to buy pain drug developer SiteOne, challenging Vertex | ||
| 27.05. | Biogen strikes RNAi deal with City; Aurion withdraws IPO | ||
| 27.05. | Patient dies in trial of Rocket gene therapy for heart condition | ||
| 27.05. | GlycoEra raises $130M, riding interest in protein degraders | ||
| 27.05. | The transformative impact of integrated informatics platforms on biopharma R&D | ||
| 27.05. | Navigating the evolving landscape of fill/finish: Challenges and what's ahead | ||
| 23.05. | FDA panel recommends keeping COVID shots targeted to same strain as last year | ||
| 22.05. | AI tool could help doctors ID breast cancers vulnerable to Enhertu | ||
| 22.05. | Zepzelca, Tecentriq combo extends survival in hard-to-treat lung cancer | ||
| 22.05. | Sanofi gains experimental Alzheimer's drug through Vigil buyout | ||
| 22.05. | House passes reconciliation bill with massive Medicaid cuts | ||
| 22.05. | Novo pressures GLP-1 compounders as FDA ban takes hold | ||
| 22.05. | FDA advisers pan Pfizer's PARP drug; Sarepta to resume Duchenne study | ||
| 21.05. | Reproductive health startup raises $65M for infertility drugs | ||
| 21.05. | FDA panel backs Darzalex for early stage multiple myeloma | ||
| 21.05. | Moderna pulls application for combo COVID, flu shot | ||
| 21.05. | Roche strikes Orionis deal to develop 'molecular glues' for cancer | ||
| 20.05. | FDA sets stricter approval standards for COVID vaccines |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .